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FluoroquinolonesAbstract Gastroretentive levoﬂoxacin (LVF) ﬂoating mini-tablets for the eradication of Helico-
bacter pylori (H. pylori) were prepared using the matrix forming polymer hydroxypropyl methylcel-
lulose (HPMC K100M), alone or with Carbopol 940P in different ratios by wet granulation
technique. Buoyancy of mini-tablets was achieved by an addition of an effervescent mixture consist-
ing of sodium bicarbonate and anhydrous citric acid to some formulations. The prepared mini-tab-
lets were evaluated for weight variation, thickness, friability, hardness, drug content, in vitro
buoyancy, water uptake and in vitro release. The optimized formula was subjected to further stud-
ies: FT-IR, DSC analysis and in vivo examination in healthy volunteers. The prepared mini-tablets
exhibited satisfactory physicochemical characteristics. Incorporation of gas-generating agent
improved the ﬂoating parameters. HPMC K100M mini-tablet formulation (F1) offered the best
controlled drug release (>8 h) along with ﬂoating lag time <1 s and total ﬂoating time >24 h.
The obtained DSC thermograms and FT-IR charts indicated that there is no positive evidence
for the interaction between LVF and ingredients of the optimized formula. The in vivo test
Gastroretentive levoﬂoxacin ﬂoating mini-tablets 571conﬁrmed the success of the optimized formula F1 in being retained in the stomach of the
volunteers for more than 4 h. LVF ﬂoating mini-tablets based on HPMC K100M is a promising
formulation for eradication of H. pylori.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Helicobacter pylori (H. pylori) infection is the causative organ-
ism in chronic active gastritis, duodenal ulcers and gastric ade-
nocarcinoma (Khalifa et al., 2010). This bacterium is highly
adapted for colonization in the human stomach, the majority
of these bacteria are free living in the gastric mucus layer
although about 20% is in close contact with epithelial cells
(Hessey et al., 1990). Antimicrobial resistance, patient’s poor
compliance with the antibiotic regimen, and drug-related side
effects are said to be the major problems with eradication of
H. pylori (Vakil, 2005). Levoﬂoxacin (LVF) is a broad
spectrum third-generation ﬂuoroquinolone antibiotic (Kassab
et al., 2010). Some studies have demonstrated that LVF
has a remarkable in vitro activity against H. pylori when its
strains are resistant to clarithromycin and metronidazole
(Antos et al., 2006). These favorable results have been con-
ﬁrmed in vivo, indicating that most of the patients with both
metronidazole and clarithromycin resistance are cured with
the LVF-based regimen. LVF has shown promising results in
different ﬁrst-line triple regimens in several countries, with
an eradication rate ranging from 72% to 96% (Gisbert and
Pajares, 2010).
Complete eradication of H. pylori requires high concentra-
tions of antibiotics to be maintained within gastric mucosa for
prolonged period of time (Nayak et al., 2010). This approach
can be achieved by preparing gastroretentive dosage forms
that ensure prolonged drug release near the ecological niche
of the bacterium (Bardonnet et al., 2006).
Floating drug delivery systems are those systems having a
bulk density less than that of the gastric ﬂuids and thus these
systems remain buoyant for a prolonged period of time in the
stomach without being affected by the gastric emptying rate.
The drug is released slowly at the desired rate from the sys-
tem and after release of the drug; the residual system is emp-
tied from the stomach (Sharma et al., 2011). Most of the
ﬂoating systems previously reported are single unit systems
such as tablets and capsules. Multiple unit ﬂoating drug deliv-
ery systems, such as pellets or mini-tablets, show several
advantages over monolithic ones, which include avoiding all
or nothing emptying, more predictable drug release kinetics,
less chance of localized mucosal damage and administration
of units with different release proﬁles or containing incompat-
ible substances (Ishak et al., 2007; Christian et al., 2011).
Mini-tablets offer an alternative for pellets because of their
relative ease of manufacturing. In addition, they offer dosage
forms of equal dimensions and weight with smooth regular
surface that could be obtained in a reproducible and contin-
uous way. Mini-tablets could be either ﬁlled into hard cap-
sules or compacted into bigger tablets (Lopes et al., 2006).
In the present study, gastroretentive ﬂoating LVF mini-tab-
lets, for the eradication of H. pylori were prepared and
evaluated.2. Materials and methods
2.1. Materials
Levoﬂoxacin hemihydrate antibiotic (Zhejiang Apeloa Kan-
gyu Pharmaceutical Co., Ltd., China). Methocel K100M
Premium DC (Hydroxypropyl methyl cellulose), with an
apparent viscosity 75,000–140,000 mPa s for a 2% solution
in water at 20 C (The Dow Chemical Company and Color-
con, Inc., USA). Carbopol 940 NF polymer, with viscosity
40,000–60,000 mPa s (0.5% mucilage at 25 C) (Lubrizol Ad-
vanced Materials, Inc., Calvert City, KY, USA). Barium sul-
fate for oral and rectal use (Commercial Firm for Chemicals
and Pharmacies Supply, Turkey). Levoxin (Amoun Pharma-
ceutical Co., Egypt). All other chemicals and solvents were of
analytical grade.
2.2. Preparation of mini-tablets by wet granulation technique
Composition of mini-tablet formulations is listed in Table 1.
All ingredients were weighed, and mixed using the geometric
dilution technique except magnesium stearate. The mixture
was granulated using isopropyl alcohol. Polyvinyl pyrrolidone
(PVP) was added as a binder to the granulating solvent by 5%
whenever needed. The obtained dough mass was passed
through 1.4 mm mesh sieve to prepare the granules. The gran-
ules were dried at 60 C in the thermostatic hot air oven. Dried
granules were ground in a mortar and then sieved. Granules
that passed sieve No. 45 (355 lm) were used. Magnesium stea-
rate was then added as 2%. Mini-tablets, weighing 50 mg, were
obtained using a single punch tablet press ﬁtted with a 4 mm
diameter concave punch. Each dose comprised 14 mini-tablets
which are equivalent to 250 mg LVF.
2.3. Evaluation of the pre-compression parameters of powder
mixtures
Pre-compression parameters: bulk density, tapped density, an-
gle of repose, Carr’s index and Hausner’s ratio (Hadi et al.,
2012), were measured.
2.4. Evaluation of the post-compression parameters of LVF
mini-tablets
Compressed mini-tablets were characterized for weight varia-
tion, crushing strength, diameter, thickness and friability as
follows:
2.4.1. Weight variation of mini-tablets
The weight variation test was conducted by weighing 20 ran-
domly selected mini-tablets individually (Rao et al., 2012).
The average weight and standard deviation were calculated.
Table 1 Composition of mini-tablet formulations.
Formula F1 F2 F3 F4 F5
Ingredients mg
Levoﬂoxacin 250
Citric Acid 65 65 65
NaHCO3 130 130 130
Carbopol 940P 218 120.5 145.3 80.3
HPMC K100M 241 218 120.5 290.6 160.6
Magnesium stearate (2%) 14
Total weight 700
572 S.A. El-Zahaby et al.2.4.2. Diameter and thickness for mini-tablets
The diameter and thickness of ten randomly selected mini-tab-
lets from each formulation were measured with a Vernier cal-
iper scale. The average and standard deviation were reported.
2.4.3. Mini-tablet crushing strength/ hardness test
Crushing strength of the mini-tablets was determined using the
tablet hardness tester (Dr. Schleuniger Pharmatron AG,
USA). Hardness was determined using six mini-tablets from
each formulation and crushing strength that just caused the
mini-tablet to break was recorded (Al Remawia et al., 2013).
The average of 6 records expressed in Newton was used.
2.4.4. Friability test for mini-tablets
Friability test was carried out by using Copley friability tester
FRV2000 (Copley Nottingham, UK) (Sathali and Ganesan,
2012).
2.4.5. Content uniformity test
Ten mini-tablets of the chosen formula (F1) were randomly se-
lected and weighed. Each one was crushed individually and
dissolved in 50 ml 0.1 N HCl. The volume was adjusted to
50 ml using 0.1 N HCl and then ﬁltered. Samples were assayed
for LVF content spectrophotometrically at predetermined kmax
294 nm and the drug concentration in each mini-tablet was cal-
culated, after suitable dilution. The drug content in each mini-
tablet was compared to the label claim.
The drug content for the other formulations was calculated
from their corresponding absorbance values at 24 h during the
release study.
Drug content for the selected formulation was also tested
by crushing 20 mini-tablets and the blend equivalent to
250 mg of LVF was weighed, dissolved in 0.1 N HCl, ﬁltered
and suitably diluted. The drug content was analyzed spectro-
photometrically at kmax 294 nm.
2.4.6. In vitro buoyancy test
In vitro buoyancy was determined by measuring buoyancy lag
time and total ﬂoating duration (Jagdale et al., 2009). The
buoyancy test was performed using the USP dissolution appa-
ratus II containing 900 ml of 0.1 N HCl as the dissolution
medium was maintained at 37 ± 0.5 C. Fourteen mini-tablets
were spread over the surface and the medium was rotated at
75 rpm for 24 h. The measurements of both ﬂoating lag time
and total ﬂoating time were carried out for each formulation.
The ﬂoating and the settled mini-tablets were also observed
visually and the results were presented as % ﬂoating after4 h. Matrix integrity was also observed throughout the
in vitro buoyancy studies.
2.4.7. In vitro drug release test and modeling of drug release
proﬁles
Fourteen mini-tablets containing 250 mg LVF were placed in
900 ml 0.1 N HCl as a dissolution medium was maintained
at 37 ± 0.5 C. Drug release was performed using a USP type
II apparatus at 75 rpm for 24 h. Aliquots of 5 ml were with-
drawn at speciﬁed intervals of time, ﬁltered and replenished
with 5 ml fresh dissolution medium. Samples’ absorbance
was measured at kmax 294 nm after suitable dilution (Mouzam
et al., 2011). The studies were performed in triplicate. The
cumulative % of LVF released was calculated at each time
interval.
Drug release data were analyzed according to zero order,
ﬁrst order, Higuchi, Hixon-Crowell, Peppas and Weibull ki-
netic equations (Dash et al., 2010). DDSolver, an add-in pro-
gram for Microsoft Excel, for modeling and comparison of
drug release proﬁles was used (Zhang et al., 2010).
The model with the highest coefﬁcient of determination
(R2) was considered to be the best ﬁtting one.
2.5. Water-uptake study
Water-uptake was carried out for all mini-tablets according to
the method adopted by Chinthala et al. (2012) with modiﬁca-
tions. The study was performed in duplicates. Mini-tablets
were individually weighed and each one was transferred into
a beaker containing 25 ml 0.1 N HCl at 37 ± 0.5 C and stir-
red at 25 rpm. At the speciﬁed intervals of time, each mini-tab-
let was gently wiped with a ﬁlter paper to remove surface
water, and re-weighed. The degree of swelling was calculated
according to the following equation:
S ¼Ws Wd
Wd
 100
where: S= the degree of swelling/swelling index or water-up-
take (%); Ws the weight of swollen mini-tablet and Wd the
weight of dry mini-tablet.
2.6. Viscosity measurement
Gels (2%) of HPMC K100M and HPMC K100M: Carbopol
1:1 and 2:1 were prepared in distilled water. Brookﬁeld RV
DV-II viscometer (Brookﬁeld Engineering Laboratories,
USA) equipped with spindle number 15 was used for viscosity
measurements. All the rheological studies were carried out at
20 C.
2.7. Fourier transform infrared (FT-IR) spectroscopy
FT-IR spectra were obtained for the pure drug, polymer and
selected formula in the range of 4000–500 cm1 using (Per-
kin-Elmer, USA).
2.8. Differential scanning calorimetry (DSC)
Samples (5 mg) of LVF, HPMC K100M, PVP, physical mix-
ture of LVF with HPMC K100M and mixture prepared by
Gastroretentive levoﬂoxacin ﬂoating mini-tablets 573wet granulation technique of LVF with HPMC K100M
using PVP as binder were accurately weighed in aluminum
pans and hermetically sealed. All samples were scanned at
10 C/min under nitrogen gas purge over temperature range
from 25–350 C.
2.9. In vivo study in healthy volunteers
Three healthy volunteers participated in the study after giving
informed written consent. The subjects’ ages ranged from 29 to
33 years and weights from 70 to 82 kg. Health status of the vol-
unteers was conﬁrmed by complete medical history and phys-
ical examination. The subjects were instructed to take no
medicines for 1 week prior to and during the course of the
study. The study was approved by the ethics committee of
faculty of medicine, Alexandria University.
To make the chosen formula (F1) X-ray opaque, 140 mg of
the drug was replaced with barium sulfate (BaSO4) and all
other ingredients were kept constant. This amount was deter-
mined experimentally to allow X-ray visibility but not to hin-
der tablet buoyancy. After overnight fasting, the volunteers
were fed with a low calorie food. The barium sulfate-labeled
fourteen mini-tablets combined in capsules were then given
to every subject with 200 ml of water. The volunteers were ex-
posed to abdominal X-ray imaging in a standing position be-
fore administration and 2 and 4 h post-administration of
mini-tablets.
2.10. Statistical analysis
The resulting data were analyzed by using the software SPSS
17.0 (SPSS Inc., Chicago, USA) applying a two-way ANOVA.
Post hoc multiple comparisons were applied when necessary.
Differences between formulations were considered to be signif-
icant at p 6 0.05.
3. Results and discussion
3.1. Pre-compression parameters of powder mixtures
The angle of repose of the powder mixture for all formulations
(F1–F5) ranged from 25.9 to 27.7 indicating excellent ﬂow
properties (Couto et al., 2013). Bulk and tapped density of
the powder mixture for all formulations varied from 0.358 to
0.455 gm/cm3 and from 0.432 to 0.581 gm/cm3, respectively.
Hausner’s ratios and compressibility indices ranged from 1.2
to 1.27 and 18.54% to 21.68%, respectively. The results of
ﬂow properties are acceptable for granules (Trivedi et al.,
2008).The values of compressibility indices further conﬁrmed
the good compressibility of the prepared granules (Wilson
et al., 2011).
3.2. Post-compression parameters for mini-tablets
Concerning appearance, the mini-tablets were light yellow,
whitish-buff or white in color, all were round concave, with
smooth surface in both sides and no visible cracks were
observed.
The mean diameter of mini-tablets was 4.0 ± 0.0 mm
while mean thickness ranged from 3.2 to 4.7 mm. Meanhardness was in the range of 31.7–54.7 N indicating that the
mini-tablets are of sufﬁcient strength to withstand physical
abrasion (Manivannan and Chakole, 2011). The percentage
friability for all formulations was less than 1% which is an
indication of satisfactory mechanical resistance of the mini-
tablets (Savic et al., 2013). The mini-tablets showed no
evidence of capping, cracking, cleavage or breaking after
being removed from the friabilator. The percentage of mean
drug content (14 mini-tablets) ranged from 95.7–98.3% which
met the standard pharmacopeial requirements (90–110%)
(Garg and Gupta, 2013).Since the mixtures of powders used
were free ﬂowing, the obtained mini-tablets were of uniform
weight due to uniform die ﬁll. The mean weight of mini-
tablets was 50 ± 0.0 mg, (n= 20). The USP speciﬁcation is
generally ±10% for tablets weighing 130 mg or less (Bano
et al., 2011). This means that no difference was observed in
the weight of individual mini-tablets from the labeled weight
indicating uniformity of weight.
3.3. In vitro buoyancy test
In the present study the ﬂoating system employed sodium
bicarbonate (NaHCO3) and citric acid in an optimized ratio
(2:1) as gas forming mixture (Pare et al., 2008). This ratio
was used in order to provide the shortest possible ﬂoating
lag time and ﬂoating duration of up to 24 h. Sodium bicarbon-
ate induced effervescence that leads to pore formation and
consequently, rapid hydration of the mini-tablets’ matrices
thus enhancing their ﬂoating ability (Tadros, 2010).
Table 2 shows the results of ﬂoating lag time and total ﬂoat-
ing time of different mini-tablet formulations (F1–F5).
Effervescent formulations containing HPMC K100M (F1,
F3 and F5) showed good ﬂoating lag time and total ﬂoating
time. This might be due to the rapid hydration and subsequent
formation of viscous gelatinous layer when HPMC K100M
was exposed to an aqueous medium (Basak and Jayakumar
Reddy, 2006). This viscous gelatinous layer prevented escape
of evolved carbon dioxide from the formed matrices leading
to decreased density, consequently, short time was needed
for ﬂoating (Prajapati et al., 2008). For effervescent (F3, F5)
and non-effervescent (F2, F4) formulations, as the ratio of
Carbopol in the polymer blend increased, the ﬂoating time de-
creased. This observation was in agreement with (Pare et al.
(2008) who stated that Carbopol had a negative effect on ﬂoat-
ing behavior and it was used only for its drug release retardant
characteristics. Another study by Li et al. (2003) showed the
same negative effect of Carbopol on the ﬂoating behavior of
the delivery system. This was explained on the basis that the
moisture gain for Carbopol is signiﬁcantly higher compared
to moisture gain for HPMC K4M (55% weight gain for Car-
bopol vs. 33% for HPMC K4M at RH of 95%) which results
in a dramatic increase in the density of the ﬂoating drug deliv-
ery system that, in turn, shows a corresponding decrease in its
ﬂoating capacity (Li et al., 2003). HPMC K100M non-efferves-
cent mini-tablet formulations, F2 and F4, showed a longer
ﬂoating lag time of 30 and 20 min and a variable total ﬂoating
time of 2 h and >24 h, respectively. Reduction in HPMC
K100M level in F2 compared to F4 mini-tablet formulations,
prolonged the ﬂoating lag time and shortened the total ﬂoating
time, this was in agreement with the previously reported study
by Shah et al. (2010).
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Figure 1 The release proﬁles for different HPMC K100M based mini-tablet formulations in 0.1 N HCl at 37 ± 0.5 C (n= 3).
Table 3 Mean and standard error of the percent LVF released
from various mini-tablet formulations (Duncan test).
Formula Mean % drug released ± SE
F1 49.76 ± 0.525b
F2 45.38 ± 0.525c
F3 49.39 ± 0.525b
F4 44.60 ± 0.525c
F5 52.96 ± 0.525a
N.B. Means of similar symbols are statistically insigniﬁcant
a > b > c.
Table 2 Floating properties of LVF mini-tablets.
Formula Floating lag time Total ﬂoating time (h)
HPMC K100M Eﬀerv. (F1) 1 s >24
HPMC K100M: Carbopol (1:1) (F2) 30 min 2
HPMC K100M: Carbopol (1:1), Eﬀerv. (F3) 1 s 8 (after 24 h half are below, half were suspended in the middle)
HPMC K100M: Carbopol (2:1) (F4) 20 min >24 (11 ﬂoated while 3 sank)
HPMC K100M: Carbopol (2:1), Eﬀerv. (F5) 1 s >24
Efferv.: containing effervescent mixture.
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water uptake
The release proﬁles of LVF from HPMC K100M based mini-
tablets are shown in Fig. 1.
Concerning effervescent formulations F1, F3 and F5: For-
mula F1 containing HPMC K100M exhibited burst release
since about 17% LVF released in 10 min. Whereas, formulae
F3 and F5 containing mixture of HPMC K100M and Carbo-
pol 940P in a ratio 1:1 and 2:1 released 5% and 10% LVF,
respectively, in 10 min. The initial burst effect for F1 could
be due to rapid dissolution of the drug from the surface while
the HPMC K100M undergoes hydration to form a protective
gel layer (Tiwari and Rajabi-Siahboomi, 2009). The addition
of Carbopol as an anionic polymer in the matrix decreased
the drug release in the acidic medium by forming an insoluble
mass that acts as a barrier to drug diffusion (Tatavarti et al.,
2004) and, consequently, the initial burst effect was decreased.
A two-way ANOVA of the percent drug released from var-
ious HPMC K100M mini-tablet formulations showed statisti-
cally signiﬁcant difference (P 6 0.0001) for the effect of the
type of formulations on the percent drug released. The results
of Duncan test (Table 3) showed that the release of LVF from
the prepared formulations was in the following order
F5 > F1 = F3 > F2 = F4.
The effervescent formulae containing HPMC K100M (F1)
and HPMC K100M: Carbopol 940P (1:1) (F3) had the same
overall mean drug released as shown in Table 3 (Duncan test).
However, the rate of drug release from F1 and F3 was differ-
ent. At 0.5 h around 27% and 17% LVF was released from F1
and F3, respectively. On the other hand, at 8 h about 80%
and 96% LVF was released from F1 and F3 mini-tablets,respectively. This could be explained based on the difference
in viscosities in each formulation. A mixture of HPMC
K100M with Carbopol 940P increased the release rate due to
the decreased amount of the more viscous polymer (HPMC
K100M) that is replaced by a less viscous polymer (Carbopol
940P). These results were conﬁrmed by viscosities’ measure-
ments where HPMC K100M showed the high viscosity, while
HPMC K100M: Carbopol (2:1) had an intermediate viscosity
and ﬁnally the (1:1) ratio had the lowest viscosity. It is obvious
that as much as the contribution of the higher viscosity poly-
mer increased the drug release decreased. It was concluded that
polymer viscosity had a major inﬂuence on the drug release
from hydrophilic matrix tablets.
Fig. 2 shows the viscosities of 2% w/v aqueous solution of
HPMC K100M either alone or in combination with Carbopol
940P in ratios (1:1) and (2:1).
Concerning F5, it showed a higher overall mean drug re-
leased than both F1 and F3 as revealed by statistical analysis
(Duncan test). Besides the effect of viscosities of the used poly-
mers, the presence of effervescent components that created
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affects LVF release patterns from F1, F3 and F5 mini-tablets.
Although F5 contains a higher proportion of the viscous
polymer (HPMC K100M) than F3, the release of LVF from
F5 was higher than from F3. The presence of the effervescent
component, sodium bicarbonate, formed a large number of
pores along the matrices of the mini-tablets. It has been also
documented that sodium bicarbonate increased the cummula-
tive amount of drug released from HPMC but not that re-
leased from Carbopol. This was explained based on the
difference in hydration characteristics of the two polymers;
the addition of sodium bicarbonate caused an increase of the
hydration volume that leads to matrix volume expansion in
case of HPMC (Gutie´rrez-Sa´nchez et al., 2008).
It is concluded that both the type of polymer used and the
presence of effervescence components affect the % of LVF re-
leased from HPMC K100M mini-tablet formulations.
Concerning the non-effervescent formulae F2 and F4 mini-
tablets containing HPMC K100M: Carbopol 940P in ratios
(1:1) and (2:1), respectively, both resulted in the same overall
mean drug released according to Duncan test. They offered
the slowest release rate among formulations containing HPMC
K100M. This could be explained based on the absence of gas-
forming agents and consequently the absence of effervescence
and pore formation. As a result there was slower hydration of
the mini- matrices leading to a slower drug release rate
(Tadros, 2010). This ﬁnding was in agreement with Tadros
(2010) who found that there was an inverse relationship be-
tween the investigated concentration of the gas forming agent
and the drug release rate.
Unfortunately, F2 and F4 mini-tablets showed 30 and
20 min ﬂoating lag time, respectively, as mentioned in Table 2.
They represented the longest ﬂoating lag time therefore they
could not be considered successful ones.0 
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Figure 3 Swelling indices of HPMC K100M mini-tablet formu-
lations after 4 h in 0.1 N HCl at 37 C.The swelling indices of different HPMC K100M mini-tablet
formulations (F1–F5) after being immersed for 4 h in 0.1 N
HCl are shown in Fig. 3.
Concerning effervescent mini-tablet formulations F1, F3
and F5:
Results revealed that F1 showed the highest % SI
(240.57%) after 4 h. This high degree of swelling is attributed
to the presence of the highly hydrophilic hydroxypropoxyl
groups in HPMC K100M (Vueba et al., 2004). The swelling
indices of both F3 and F5 formulations were less than that
of F1 at the same time. This resulted in a higher percent drug
released from both F3 and F5 at 4 h compared to F1 as shown
in Fig. 2. The differences in swelling indices for F1, F3 and F5
could be due to a lesser proportion of the hydrophilic polymer
HPMC K100M in both F3 and F5 compared to F1.
Concerning non-effervescent mini-tablet formulations F2
and F4:
The % SI for F2 (237%) and F4 (240%) were nearly equal
which supported the statistical insigniﬁcant difference in their
overall mean drug released according to Duncan test (Table 3).
The swelling indices of the non-effervescent formulae (F2
and F4) were greater than their corresponding effervescent for-
mulae (F3 and F5), respectively. This could be a reason for the
lower mean drug released observed from F2 and F4 compared
to that of F3 and F5 mini-tablets as previously mentioned in
Duncan test (Table 3).
The carbon di-oxide bubbles produced by sodium bicar-
bonate expand the matrices facilitating the drug dissolution
and their presence might also obstruct the diffusion path
through the hydrated gel layer (Lara-Herna´ndez et al., 2009).
This explains the difference in release and swelling behaviors
between the effervescent and non effervescent mini-tablet
formulations.
All HPMC K100M mini-tablet formulations (F1–F5) kept
their integrity throughout the swelling studies.
Over time, the matrix of the tablets was deformed because
there is a slow diminution of the matrix thickness due to poly-
mer dissolution. The polymer in the matrix undergoes simulta-
neous swelling, dissolution and diffusion into the bulk
medium, resulting in erosion and reduction of the matrix
strength. It is also considered that the gas bubbles dissipating
from the inside to the outside of the matrix debilitate the ma-
trix structure (Lara-Herna´ndez et al., 2009).
To explain the release kinetics of LVF from mini-tablets,
the data of in vitro release experiment were treated according
to the model-dependent methods, zero order, ﬁrst order, Hig-
uchi model, Korsmeyer–Peppas model, Hixson–Crowell model
and Weibull equation.
Criteria for selecting the most appropriate model was based
on best ﬁt indicated by the value of coefﬁcient of determina-
tion (R2) nearer to 1 (Prabakaran et al., 2003).
Concerning F1, F2 and F4 the highest values of R2 were ob-
tained after ﬁtting the data into Peppas equation. The value of
(n) allows the release to be characterized as either Fickian
diffusion n 6 0.5, anomalous diffusion (non-Fickian)
(0.5 < n< 1) or zero-order release (n= 1) (Costa and Sousa
Lobo, 2001). The n values for F2 and F4 were 0.53 and 0.56
respectively, that indicated anomalous diffusion (non-Fickian)
which refers to a combination of both diffusion and erosion
controlled-drug release (Sabar et al., 2011). Whereas, the value
of (n) in case of F1 (n= 0.39) revealed a Fickian diffusion
mechanism of LVF from these mini-tablets.
Figure 4 DSC thermograms for: (a) LVF hemihydrate, (b) the mixture of LVF and HPMC K100M prepared by wet granulation
technique using isopropyl alcohol and PVP and (c) the physical mixture of LVF and HPMC K100M.
576 S.A. El-Zahaby et al.F3 had the same coefﬁcient of determination, R2 = 0.999,
for ﬁrst order as well as for Weibull equation. The ﬁrst order
describes the release from system where release rate is concen-
tration dependent therefore LVF released from F3 mini-tablets
was proportional to the amount of LVF remaining in its inte-
rior, in such way, that the amount of LVF released diminishedby unit of time (Costa and Sousa Lobo, 2001). Weibull model
helped in describing the shape of the release curve of F3 de-
duced from its b value (1.02) which was found to be exponen-
tial (Costa and Sousa Lobo, 2001).
F5 followed Weibull’s equation (R2 = 0.999). F5 had b va-
lue (0.87) so the curve was supposed to be parabolic, with a
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Figure 5 Comparison of the release proﬁles of optimized
formula F1 and marketed LVF (Levoxin) in 0.1 N HCl at
37 ± 0.5 C.
Figure 6 X-ray photographs of the gastric region of a healthy
volunteer: (a) before administration of mini-tablets, (b) 2 h after
dosing of mini-tablets-in-capsule system in the fed state and (c) 4 h
after dosing in the same condition. N.B. b and c show LVF mini-
tablets ﬂoating over the gastric content of a volunteer.
Gastroretentive levoﬂoxacin ﬂoating mini-tablets 577higher initial slope and after that consistent with the exponen-
tial (Costa and Sousa Lobo, 2001).
Based on the above results, it concluded that the efferves-
cent LVF mini-tablet formulation (F1) that contained HPMC
K100M was optimum, with respect to its acceptable post-com-
pression parameters, its excellent ﬂoating characteristics as
well as its prolonged drug release. It could provide such con-
trolled release proﬁle using single polymer which is more ben-
eﬁcial as it decreases the liability to any drug–polymer
interaction or any incompatibility between ingredients of the
prepared mini-tablets. Therefore F1 was selected for further
studies; FT-IR spectroscopy, DSC, comparison to the mar-
keted LVF product (Levoxin) and in vivo test.
3.5. FT-IR spectroscopy and DSC studies
Drug-excipients compatibility study to F1 formulation was
conducted using FT-IR spectroscopy and DSC study. IR spec-
tra were obtained for LVF, polymer used and a blend of them
prepared by wet granulation technique.
The LVF FT-IR charts got characteristic absorption peaks
for the –OH group of the –COOH moiety at around
3261.4 cm1 and –C‚O peak near 1725.1 cm1. The aromatic
C–H peaks are also observed in the range 2900–3000 cm1.
Charts for mixture of LVF with HPMC K100M polymer used
in mini-tablet formulations exhibited characteristic absorption
peaks in the same range of pure drug peaks. Hence, it could be
conﬁrmed that there is no interaction between drug and excip-
ients in this formulation (Doodipala et al., 2011).
DSC study for the selected formulation F1, was also con-
ducted. The thermograms of drug, physical mixture of drug
and HPMC K100M, and a mixture (LVF, HPMC K100M
and PVP) prepared by wet granulation technique are shown
in Fig. 4. The LVF DSC thermogram (Fig. 4a) showed an
endothermic peak at 91 C due to the dehydration of LVF
hemihydrate. In addition an endothermic peak at 227 C
due to the melting of the c form, an endothermic peak at
230 C due to the melting of the b form and an endothermic
peak at 231 C due to the melting of the a form were also ob-
served. Kitaoka et al. (1995) studied the effect of dehydration
on the formation of LVF pseudopolymorphs and the effect of
heating rate on DSC curves of LVF.In the present study, the LVF peaks were in agreement with
the documented DSC chart in the literature under the same
heating rate 10 C/min (Kitaoka et al., 1995). The observed
exothermic peaks might be due to the crystallization of an
amorphous form that resulted partially from LVF dehydration
(Kitaoka et al., 1995). The DSC thermogram of the optimized
formulation (F1) showed a slight change in the peak shape
with little broadening (Fig. 4c) which could be attributed to
the mixing process that lowers the purity of each component
in the mixture (Verma and Garg, 2004). The obtained thermo-
grams indicated that there is no positive evidence for the
578 S.A. El-Zahaby et al.interaction between LVF and ingredients of the optimized
formulation.
3.6. Comparison of the selected mini-tablet formulations with the
marketed LVF product (Levoxin)
The results of the comparative in vitro release study of opti-
mized formula F1 with marketed LVF (Fig. 5) showed that
F1 released 28.52% LVF in 30 min, whereas the marketed
product released 97.25% LVF in the same duration. F1 re-
leased 82.1% LVF in 8 h with T50% of 126.8 min and ﬂoating
lag time <1 s and total ﬂoating time >24 h.
3.7. In vivo test
It has to be pointed out that good in vitro ﬂoating behavior
alone is not a sufﬁcient proof for efﬁcient gastric retention
in vivo. The effects of simultaneous presence of food and of
the complex motility of the stomach are difﬁcult to estimate.
Obviously in vivo studies can provide a deﬁnite proof that pro-
longed gastric residence could be obtained.
A radiological method was adopted to monitor the units in
the gastric region of humans in feeding conditions. The ob-
tained radiographs obtained at 0, 2 and 4 h are shown in
Fig. 6. At zero time, the stomach was free from any radio-opa-
que materials. Almost all of the ﬂoating mini-tablets were still
buoyant on the gastric content up to 4 h.
4. Conclusion
According to the above results, HPMC K100M mini-tablet
formulation (F1) offered best LVF controlled release along
with ﬂoating lag time <1 s and total ﬂoating time >24 h.
The optimized formula (F1) showed the absence of interaction
between LVF and the used polymer/additives which conﬁrmed
the compatibility among its ingredients. In vivo studies can
provide a deﬁnite proof that prolonged gastric residence could
be obtained. The in vivo test conﬁrmed the success of the opti-
mized formula (F1) in being retained in the stomach of the vol-
unteer over the tested period providing localized LVF release.References
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